Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Shots: Ethris has entered into a collaboration agreement with Lonza to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery in pts with respiratory diseases As per the deal, Lonza will support Ethris’ vaccine candidates, which are based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) & stabilized lipid nanoparticles (SNaP LNP)…

ByRidhi RastogiApril 7, 2025

PharmaShots Magazine-March-2025 Edition

Did you know that 60 percent of pharmaceutical production is outsourced? As drug development costs rise, CDMOs have become safe havens for biopharma companies by offering scalable, cost-effective, and cutting-edge technology solutions for drug development and manufacturing. In March, PharmaShots Magazine is navigating the evolving Biopharma CDMO frontier by decoding trends, illustrative infographics, thought-provoking articles,…

ByAditya SinghMarch 13, 2025

20 Contract Development and Manufacturing Organizations (CDMO) of 2024

Shots: CDMOs are at the forefront of pharmaceutical manufacturing, shaping the industry's growth by meeting the increasing global demand for pharmaceutical products In 2023, the global CDMO market was valued at $224.86B, with projections to reach $465.14B by 2032, demonstrating a CAGR of 8.5% PharmaShots presents a comprehensive report on the 20 Contract Development and…

ByPrince GiriNovember 14, 2024

Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

PharmaShots Magazine-March-2025 Edition

20 Contract Development and Manufacturing Organizations (CDMO) of 2024

Contact US

OUR INFORMATION

FOLLOW US